Isis (Not yet branded)
Targeted Therapy
Description
ISIS refers to antisense oligonucleotide compounds developed by Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals) that have been evaluated in colorectal cancer treatment. ISIS 2503 targets H-ras mRNA to reduce oncogenic H-ras protein production, while ISIS 183750 targets protein tyrosine phosphatase 1B (PTP1B) and has been combined with irinotecan in advanced colorectal cancer. These antisense oligonucleotides are designed to bind to specific mRNA sequences and prevent translation of proteins that promote cancer cell growth and survival.
Mechanism of Action
ISIS 2503 works by binding to H-ras mRNA through complementary base pairing, leading to mRNA degradation and reduced production of the H-ras oncoprotein that drives cell proliferation. ISIS 183750 targets PTP1B mRNA, reducing PTP1B protein levels which normally inhibit insulin and growth factor signaling pathways involved in cancer progression.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Targeted Therapy |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.